Sangita B. Patel

Statistics

Publications

Citations

3.7K

H-Index

Active since

1989

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Merck Canada Inc. (Canada)

Sangita B. Patel is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

1989–2021

Publications

(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40

Jun Lu, Noel Byrne, John Wang et al. · Nature Structural & Molecular Biology · 2017 · 194 citations

Life Sciences, Biochemistry, Molecular Biology +16

Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity

Catherine E. Fitzgerald, Sangita B. Patel, Joseph W. Becker et al. · Nature Structural & Molecular Biology · 2003 · 182 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes

Tesfaye Biftu, Ranabir SinhaRoy, Ping Chen et al. · Journal of Medicinal Chemistry · 2014 · 167 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

Aimin Tang, Zhifeng Chen, Kara S. Cox et al. · Nature Communications · 2019 · 152 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

1–5 of 45